Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 138Breast Neoplasms 95Neoplasms 8Neoplasm Metastasis 6Breast Neoplasms, Male 6Advanced Breast Cancer 4Salivary Gland Neoplasms 3Prostate Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Osteoporosis 2Leiomyoma 2Infertility 2Advanced Prostate Cancer 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Sarcopenia 1Radiation Injuries 1Primary Ovarian Insufficiency 1Primary Dysautonomias 1Patients With T1-4 Advanced Prostate Cancer 1Patient Compliance 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Osteitis Deformans 1Myofibroma 1Lymphatic Metastasis 1Kidney Diseases 1Inflammatory Breast Neoplasms 1

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer Patients with Oligometastases × Goserelin × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡